[1] Braestrup C,Squires R F.Specific benzodiazepine receptors in rat brain characterized by high- affinity (3H) diazepam binding [J]. Proc Natl Acad Sci, 1977,74(9): 3805-3809.
[2] Braestrup C, Albrechtsen R, Squires R F. High densities of benzodiazepine receptors in human cortical areas[J]. Nature,1977,269(5630): 702-704.
[3] Zisterer D M, Williams D C. Peripheral-type benzodiazepine receptors [J]. Gen Pharmacol, 1997, 29(3):305-314.
[4] Papadopoulos V, Baraldi M, Guilarte T R,
et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function [J]. Trends Pharmacol Sci, 2006, 27(8): 402-409.
[5] Rupprecht R, Papadopoulos V, Rammes G,
et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders [J]. Nat Rev Drug Discov, 2010, 9(12): 971-988.
[6] Tu L N, Morohaku K, Manna P R,
et al. Peripheral benzodiazepine receptor/translocator protein global knockout mice are viable with no effects on steroid hormone biosynthesis [J]. J Biol Chem, 2014, 289(40): 27444-27454.
[7] Kumar A, Muzik O, Shandal V,
et al. Evaluation of age-related changes in translocator protein (TSPO) in human brain using (11)C-[R]-PK11195 PET [J]. J Neuroinflammation, 2012, 9: 232.
[8] Lang S. The role of peripheral benzodiazepine receptors (PBRs) in CNS pathophysiology [J]. Curr Med Chem, 2002, 9(15): 1411-1415.
[9] 陈春富,郎森阳,左萍萍, 等. D-半乳糖致衰老大鼠脑海马外周型苯二氮
受体改变及其与认知行为的相关研究[J]. 中华医学杂志, 2006,86(21):1470-1473.
[10] Brown R C, Han Z, Cascio C,
et al. Oxidative stress-mediated DHEA formation in Alzheimercs disease pathology[J]. Neurobiol Aging, 2003,24(1):567-572.
[11] Ji B, Maeda J, Sawada M,
et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer’s and other CNS pathologies [J]. J Neurosci, 2008, 28(47): 12255-12267.
[12] Chen, M K, Baidoo K, Verina T,
et al. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization [J]. Brain, 2004,127(Pt 6):1379-9132.
[13] Boche D, Nicoll JA. Neuroinflammation in ageing and in neurodegenerative disease [J]. Neuropathol Appl Neurobiol,2013, 39(1): 1-2.
[14] Bae K R, Shim H J, Balu D,
et al. Translocator Protein 18 kDa Negatively Regulates Inflammation in Microglia [J]. J Neuroimmune Pharmacol, 2014,9(3):424-437.
[15] Tokay T, Hachem R, Masmoudi-Kouki O,
et al. Beta-amyloid peptide stimulates endozepine release in cultured rat astrocytes through activation of N-formyl peptide receptors [J]. Glia, 2008,56(13):1380-1389.
[16] Irwin R W, Brinton R D. Allopregnanolone as regenerative therapeutic for Alzheimer’s disease: translational development and clinical promise [J]. Prog Neurobiol, 2014,113:40-55.
[17] Ferrarese C, Appollonio I, Frigo M,
et al. Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia [J]. Neurology, 1990,40(4):632-635.
[18] Kannan S, Balakrishnan B, Muzik O,
et al. Positron emission tomography imaging of neuroinflammation [J]. J Child Neurol, 2009,24(9): 1190-1199.
[19] Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders [J]. Front Pharmacol, 2012, 3: 96.
[20] Pavese N, Gerhard A, Tai Y F,
et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study [J]. Neurology, 2006, 66(11): 1638-1643.
[21] Rissanen E, Tuisku J, Rokka J,
et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195 [J]. J Nucl Med, 2014, 55(6): 939-944.
[22] Turner M R, Cagnin A, Turkheimer F E,
et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C] (R)-PK11195 positron emission tomography study [J]. Neurobiol Dis, 2004, 15(3): 601-609.
[23] Venneti S, Lopresti B J, Wang G,
et al. PK11195 labels activated microglia in Alzheimer’s disease and in vivo in a mouse model using PET [J]. Neurobiol Aging, 2009, 30(8): 1217-1226.
[24] Hommet C, Mondon K, Camus V,
et al. Neuroinflammation and β amyloid deposition in Alzheimer’s disease: in vivo quantification with molecular imaging [J]. Dement Geriatr Cogn Disord, 2014, 37(1-2): 1-18.
[25] Veiga S, Carrero P, Pernia O,
et al. Translocator protein 18 kDa is involved in the regulation of reactive gliosis [J]. Glia, 2007, 55(14):1426-1436.
[26] Bordet T, Buisson B, Michaud M,
et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis [J]. J Pharmacol Exp Ther, 2007, 322(2):709-720.
[27] Barron A M, Garcia-Segura L M, Caruso D,
et al.Ligand for translocator protein reverses pathology in a mouse model of Alzheimer’s disease [J]. J Neurosci, 2013, 33(20): 8891-8897.
[28] Choi J, Ifuku M, Noda M,
et al. Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state [J]. Glia, 2011, 59(2): 219-230.
[29] Choi H B, Khoo C, Ryu J K,
et al. Inhibition of lipopolysaccharide-induced cyclooxygenase-2, tumor necrosis factor-alpha and [Ca
2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195 [J]. J Neurochem, 2002, 83(3): 546-555.
PDF(760 KB)
